Clinical Study

Eovist Gadoxetate Sodium Enhanced Magnetic Resonance Imaging (Mri) As A Biomarker For Aggressive Prostate Cancer

Posted Date: Jun 10, 2019

  • Investigator: Sadhna Verma
  • Specialties: Cancer, Oncology, Prostate Cancer
  • Type of Study: Device

To determine if Gadoxetate Sodium has the same ability as gadolinium to identify prostate cancer by comparing enhancement ratios and to test if the diagnosis from Gadoxetate Sodium imaging can identify more aggressive prostate cancer that are likely to occur.


To Be Eligible You Must Be At Least 18 Years Of Age, Have Clinically Localized Prostate Cancer, And Normal Liver Function. No Prostatectomy, Chronic Kidney Disease Or Pacemakers.


Prostate Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.